This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

With investors and drugmakers increasingly eyeing the kidney disease space, a new company hopes to shed its underdog status ...

The idea of making the U.S. more like Europe is anathema to many in the Trump administration. But that’s what the Make ...

Next month will be the first opportunity to gauge the commercial launch of a new treatment for Prader-Willi syndrome, a rare ...

The U.S. has now recorded more confirmed measles cases this year than in any year in well over a quarter-century.

The FDA published more than 200 letters that it sent to companies when it rejected their medicines, but the letters came with a caveat.

Nearly 1 in 3 American adolescents have prediabetes, a CDC report finds. An official notes "it’s not too late to change ...

Summa Health's experience with Sepsis Watch shows the difficulties in implementing AI in a community hospital.

A systematic review of almost 50 randomized clinical trials brings some clarity to concerns about antidepressant withdrawal.